sabcs 2010 intro
Dear Colleague: Targeted therapies and personalized medicine have become two major buzzwords in cancer care. But as breast cancer specialists, we have incorporated both into our practice for some time. For instance, tamoxifen is a targeted therapy, although we didn’t necessarily call it by that name. When it comes to personalized medicine, one of our goals has been to find better prognostic and predictive factors: Can we identify which patients will benefit from a specific therapy? Can we pinpoint those patients who can safely avoid chemotherapy? The 2010 San Antonio Breast Cancer Symposium (SABCS) offers all breast cancer specialists the chance to explore the wealth of data that we have amassed over the years. Join Oncology NEWS International for onsite reports from SABCS 2010 as we bring you a bird’s eye view of the research, trials, scientific advances, and controversies that are changing the way breast cancer is managed and treated. Check back here daily during the meeting and watch your inbox for our exciting reports from the SABCS 2010.
San Antonio Breast Cancer Symposium
Dear Colleague:
Targeted therapies and personalized medicine have become two major buzzwords in cancer care. But as breast cancer specialists, we have incorporated both into our practice for some time. For instance, tamoxifen is a targeted therapy, although we didn’t necessarily call it by that name. When it comes to personalized medicine, one of our goals has been to find better prognostic and predictive factors: Can we identify which patients will benefit from a specific therapy? Can we pinpoint those patients who can safely avoid chemotherapy?
The 2010 San Antonio Breast Cancer Symposium (SABCS) offers all breast cancer specialists the chance to explore the wealth of data that we have amassed over the years. Join Oncology NEWS International for onsite reports from SABCS 2010 as we bring you a bird’s eye view of the research, trials, scientific advances, and controversies that are changing the way breast cancer is managed and treated.
Check back here daily during the meeting and watch your inbox for our exciting reports from the SABCS 2010.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
